Clinical Trial Update: AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating AMG 208 for the tumor microenvironment in metastatic castration-resistant prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• AMG 208

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN